Screener
Sana Biotechnology SANA Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 8,124 | 8,679 |
| Operating lease liabilities | 14,878 | 14,938 |
| Contingent consideration | 53,556 | 40,200 |
| Total current liabilities | 86,265 | 78,726 |
| Operating lease liabilities, net of current portion | 60,450 | 63,924 |
| Contingent consideration, net of current portion | 80,907 | 83,518 |
| Success payment liabilities | 16,926 | 19,238 |
| Other non-current liabilities | 9,805 | 10,600 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's total current liabilities?
- Sana Biotechnology (SANA) reported total current liabilities of $86.27M in Q1 2026.
- How has Sana Biotechnology's total current liabilities changed year-over-year?
- Sana Biotechnology's total current liabilities increased by 160.2% year-over-year, from $33.16M to $86.27M.
- What is the long-term trend for Sana Biotechnology's total current liabilities?
- Over 5 years (2020 to 2025), Sana Biotechnology's total current liabilities has grown at a 20.1% compound annual growth rate (CAGR), from $31.45M to $78.73M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Sana Biotechnology's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude